Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)

Recruiting

Conditions: Lung Adenocarcinoma
Pathology
Surgical Procedure, Unspecified

Interventions: Procedure: Surgical resection

First Posted Date: 2023-04-03

Last Posted Date: 2023-07-24

Lead Sponsor: Fudan University

Target Recruit Count: 1063

Registration Number: NCT05794711

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016)

Recruiting

Conditions: Pathology
Lung Adenocarcinoma
Surgical Procedure, Unspecified

Interventions: Procedure: Surgical resection

First Posted Date: 2023-04-03

Last Posted Date: 2023-07-24

Lead Sponsor: Fudan University

Target Recruit Count: 1063

Registration Number: NCT05794724

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1014)

Recruiting

Conditions: Lung Adenocarcinoma
Surgical Procedure, Unspecified
Pathology

Interventions: Procedure: Surgical resection

First Posted Date: 2023-04-03

Last Posted Date: 2023-07-24

Lead Sponsor: Fudan University

Target Recruit Count: 1063

Registration Number: NCT05794698

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）

Phase 2

Recruiting

Conditions: Advanced Biliary Tract Cancer

Interventions: Drug: Sintilimab
Drug: Lenvatinib
Procedure: Cryoablation

First Posted Date: 2023-03-23

Last Posted Date: 2023-03-24

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05781074

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Phase 2

Recruiting

Conditions: Stage II-IIIA
Neoadjuvant Therapy
Non-small Cell Lung Cancer
Immunotherapy

Interventions: Drug: Serplulimab and Chemotherapy

First Posted Date: 2023-03-20

Last Posted Date: 2023-07-12

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT05775796

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Phase 1

Recruiting

Conditions: High-Risk Localized Soft Tissue Sarcoma

Interventions: Drug: Pegylated Liposomal Doxorubicin
Drug: Doxorubicin
Drug: Anti-PD-1 monoclonal antibody
Radiation: Radiotherapy

First Posted Date: 2023-03-17

Last Posted Date: 2023-03-17

Lead Sponsor: Fudan University

Target Recruit Count: 52

Registration Number: NCT05774275

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Nimotuzumab
Drug: Camrelizumab
Drug: neoadjuvant chemotherapy and CCRT

First Posted Date: 2023-03-16

Last Posted Date: 2023-03-16

Lead Sponsor: Fudan University

Target Recruit Count: 459

Registration Number: NCT05772208

Locations: 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer
Microsatellite Stable Colorectal Carcinoma

Interventions: Drug: Vitamin E
Drug: Fruquintinib
Drug: Tislelizumab

First Posted Date: 2023-03-16

Last Posted Date: 2023-03-16

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05771181

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases

Not Applicable

Recruiting

Conditions: Nasopharyngeal Carcinoma
Liver Metastases

Interventions: Procedure: Hepatectomy

First Posted Date: 2023-03-16

Last Posted Date: 2023-05-19

Lead Sponsor: Fudan University

Target Recruit Count: 55

Registration Number: NCT05771025

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Phase 3

Recruiting

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: Famitinib
Drug: Camrelizumab
Drug: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin

First Posted Date: 2023-03-08

Last Posted Date: 2024-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 223

Registration Number: NCT05760378

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy